Institution
Beatson West of Scotland Cancer Centre
Healthcare•Glasgow, Scotland, United Kingdom•
About: Beatson West of Scotland Cancer Centre is a healthcare organization based out in Glasgow, Scotland, United Kingdom. It is known for research contribution in the topics: Cancer & Population. The organization has 489 authors who have published 1031 publications receiving 41277 citations. The organization is also known as: Beatson Oncology Centre.
Topics: Cancer, Population, Gemcitabine, Prostate cancer, Radiation therapy
Papers
More filters
••
TL;DR: It is suggested that palliative docetaxel chemotherapy can be given in patients with metastatic ductal prostate cancer with good PSA and a clinical response, and that the response observed was not durable in this case and experience would suggest that the ductal variant is an aggressive subtype with a poor outcome.
4 citations
••
31 Aug 2021TL;DR: This review describes the most common representative technologies for each type along with their advantages and current limitations as they pertain to the treatment of multiple intracranial metastases and the different strengths and limitations attributed to each technology in the case of MIM.
Abstract: The use of stereotactic radiosurgery to treat multiple intracranial metastases, frequently concurrently, has become increasingly common. The ability to accurately and safely deliver stereotactic ra...
4 citations
••
The Royal Marsden NHS Foundation Trust1, University of Southampton2, University College Hospital3, Blackpool Victoria Hospital4, Churchill Hospital5, Manchester Academic Health Science Centre6, Royal Cornwall Hospital7, St Bartholomew's Hospital8, Beatson West of Scotland Cancer Centre9, Gloucestershire Hospitals NHS Foundation Trust10, Royal Hallamshire Hospital11, Royal Liverpool University Hospital12, Torbay Hospital13
TL;DR: A parsimonious GEP assay applicable to a routine diagnostic workflow to differentiate the main P TCL entities and characterize the heterogeneity of PTCL‐NOS is developed and its simplicity and applicability on FFPE samples makes it an attractive alternative to high throughout GEP approaches.
Abstract: cases thus remain not classifiable (PTCL Not Otherwise Specified, NOS) and there is an important need for alternative diagnostic strategies. Here, we developed a parsimonious GEP assay applicable to a routine diagnostic workflow to differentiate the main PTCL entities and characterize the heterogeneity of PTCL‐NOS. A Reverse Transcriptase‐Multiplex Ligation dependant Probe Amplification (RT‐MLPA) assay was designed to evaluate the expression of 20 markers. It simultaneously addresses the expression of 18 genes routinely tested by immunohistochemistry (IHC) or selected from GEP studies. It also assesses the EBV infection status (EBER1) and the presence of RHOAG17 V and IDH2R172K/T mutations. Unsupervised hierarchical clustering of RT‐MLPA data from 102 control cases validated the capacity of our assay to identify the main PTCL entities. All Angioimmunoblastic T‐cell lymphomas (AITL; n = 29), Anaplastic largeT‐cell lymphomas (ALCL; n = 23) ALK+, NK/T‐cell lymphomas (NKTCL; n = 16), Hepatosplenic T‐cell lymphomas (HSTL; n = 6) and Adult T‐cell Leukemia/Lymphomas (ATLL; n = 12) were correctly identified. AITLs classified according to the expression of Tfh markers (CXCL13, CXCR5, ICOS, BCL6) and RHOA mutations (n = 18); NKTCLs according to EBER1, GZMB and Th1 markers (TBX21, IFNγ); HSTLs to CD56, GATA3, TBX21 and BCL6; ALCL ALK+ according to CD30, ALK and cytotoxic markers (PRF, GZMB); ATLLs to ICOSand Th2 markers (GATA3, CCR4). Interestingly, ALCL ALK‐ cases (n = 16) divided into two CD30+ subgroups: one associated with expressions of cytotoxic markers which clustered with ALCL ALK+ cases (n = 10), and a second which did not expressed PRF and GZMB but the two GATA3 and CCR4 Th2 markers (n = 6). We next developed a support vector machine based predictor combined with a centroid categorization. Applied to a series of 125 PTCL‐NOS, this algorithm reclassified 36 Tfh (AITL‐ like), 6 CD30/Th2, 6 ALCL ALK‐ like, 3 HSTL‐like and 5 NKTCL‐like PTCLs. After exclusion of these cases, unsupervised clustering analysis identified 17 cytotoxic/Th1 (GZMB, PRF,TBX21, IFNγ) cases, 14 Th2 (GATA3, CCR4) cases and 14 TH2/Tfh (GATA3, CCR4, CXCR5, ICOS) cases. Finally, 24 cases (10.5% of the cohort) did not show any recognizable signature. This study demonstrates the applicability of a robust RT‐MLPA classifier for the classification of PTCLs. Its simplicity and its applicability on FFPE samples makes it an attractive alternative to high throughout GEP approaches. In combination with conventional pathological evaluation and IHC, it may participate to improve the classification of PTCLs and the management of these aggressive tumors.
4 citations
••
TL;DR: PFS in patients with platinum-sensitive relapsed ovarian cancer who received maintenance olaparib was similar irrespective of s or g BRCAm status, as well as HRQoL and tolerability, which were consistent with previous olAParib studies in this population.
4 citations
••
4 citations
Authors
Showing all 491 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stan B. Kaye | 92 | 449 | 35666 |
Tessa L. Holyoake | 65 | 272 | 18780 |
Jim Cassidy | 64 | 217 | 20828 |
John Bellamy Foster | 59 | 531 | 15649 |
James Paul | 59 | 252 | 13394 |
Hani Gabra | 53 | 200 | 23073 |
Iain A. McNeish | 52 | 228 | 17880 |
Richard H. Wilson | 50 | 188 | 8989 |
David K. Chang | 48 | 126 | 14460 |
Thomas J. Evans | 48 | 143 | 13144 |
Robert Jones | 46 | 262 | 16459 |
Nigel B. Jamieson | 44 | 131 | 10913 |
T.R. Jeffry Evans | 41 | 113 | 7283 |
Anthony J. Chalmers | 35 | 133 | 4254 |
Mhairi Copland | 33 | 121 | 4795 |